0001193125-22-094454.txt : 20220404 0001193125-22-094454.hdr.sgml : 20220404 20220404080103 ACCESSION NUMBER: 0001193125-22-094454 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220404 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220404 DATE AS OF CHANGE: 20220404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 22800410 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 8-K 1 d348818d8k.htm 8-K 8-K
AMEDISYS INC false 0000896262 0000896262 2022-04-04 2022-04-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 4, 2022

Commission File Number: 0-24260

 

 

 

LOGO

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   11-3131700

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   AMED   The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


SECTION 7 - REGULATION FD

 

Item 7.01.

Regulation FD Disclosure.

On April 4, 2022, Amedisys, Inc. (the “Company”) issued a press release announcing that the Company has closed on its acquisition of Evolution Health, LLC, a provider of home health services, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. Also on April 4, 2022, the Company issued a press release announcing that it has closed on its acquisition of certain home health assets from AssistedCare Home Health, Inc., and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas, respectively, a copy of which is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

  

Description

99.1    Press Release dated April 4, 2022 (announcing the closing of the Evolution Health, LLC acquisition)
99.2    Press Release dated April 4, 2022 (announcing the closing of the acquisition of home health assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC)
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AMEDISYS, INC.
By:  

/s/ Paul B. Kusserow

  Paul B. Kusserow
  Chief Executive Officer and Chairman of the Board
DATE: April 4, 2022
EX-99.1 2 d348818dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Amedisys Completes Acquisition of Evolution Health

BATON ROUGE, La., April 4, 2022 – (GLOBE NEWSWIRE) – Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its acquisition of Evolution Health, LLC, a provider of home health services. Evolution Health, LLC, a division of Envision Healthcare, is doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati in 15 locations across Texas, Oklahoma and Ohio. Amedisys has acquired 100 percent of the ownership interests in Evolution Health.

“By continuing the great care provided by Guardian Healthcare, Gem City, and Care Connection of Cincinnati, Amedisys can now offer both home health and hospice services in more communities across Texas, Oklahoma and Ohio,” said Amedisys President and Chief Operating Officer Chris Gerard. “Amedisys is proud to expand its presence in these healthcare communities and provide more comprehensive care by aligning with our Amedisys Hospice footprint in these markets.”

Amedisys’ home health operations now include 350 care centers in 34 states and the District of Columbia, with an average daily census of approximately 74,000 patients and approximately 11,000 home health employees.

In 2021, Modern Healthcare named Amedisys, Inc. to its prestigious Best Places to Work in Healthcare list. Amedisys is the second largest provider of home health care and the third largest provider of hospice care in the United States with 530 locations across 38 states and the District of Columbia. As of the January 2022 Home Health Compare release, Amedisys’ Quality of Patient Care (QPC) Star score is 4.33. The Company also provides hospice care, personal care, palliative care and high-acuity care.

 

Media Contact:    Investor Contact:
Kendra Kimmons    Nick Muscato
Vice President of Marketing & Communications    Vice President of Strategic Finance
225-299-3708    615-928-5452
kendra.kimmons@amedisys.com    nick.muscato@amedisys.com

About Evolution Health

Evolution Health is a home health company headquartered in Dallas, Texas, serving three states through its family of trusted local brands. Working in partnership with the patient’s physician, Evolution Health offers traditional home health services reimbursed by Medicare, Medicaid and commercial payers including skilled nursing, occupational, physical and speech therapy, counseling and emotional support. Evolution Health’s highest priority is to provide quality, compassionate care to its patients, their families, and the communities in which they serve. For more information, visit https://www.evolution.net/.


About Amedisys

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 530 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com.

Forward-Looking Statements:

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “could,” “would,” “should,” “will” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, the impact of current and proposed federal, state and local vaccine mandates, including potential staffing shortages, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.


Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

#     #     #

EX-99.2 3 d348818dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

Amedisys Completes Acquisition of Home Health Assets from

AssistedCare Home Health and AssistedCare of the Carolinas

BATON ROUGE, La., April 4, 2022 – (GLOBE NEWSWIRE) – Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its acquisition of certain home health assets from AssistedCare Home Health, Inc., and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas, respectively.

While AssistedCare’s home health care services have transitioned to Amedisys Home Health, their personal care services are remaining with Eldercare at Home, and their Intellectual & Developmental Disabilities (IDD) and Private Duty Nursing (PDN) services remain operational as AssistedCare, Inc., and are not included in the transaction.

“By continuing the great care provided by AssistedCare Home Health and AssistedCare of the Carolinas, Amedisys can now offer both home health and hospice services in more communities across North Carolina, including those in and around Wilmington and Greenville,” said Amedisys President and Chief Operating Officer Chris Gerard. “Amedisys is proud to expand its presence in these healthcare communities and provide more comprehensive care by aligning with our Amedisys Hospice footprint in North Carolina.”

Amedisys’ home health operations now include 350 care centers in 34 states and the District of Columbia, with an average daily census of approximately 74,000 patients and approximately 11,000 home health employees.

In 2021, Modern Healthcare named Amedisys, Inc. to its prestigious Best Places to Work in Healthcare list. Amedisys is the second largest provider of home health care and the third largest provider of hospice care in the United States with 530 locations across 38 states and the District of Columbia. As of the January 2022 Home Health Compare release, Amedisys’ Quality of Patient Care (QPC) Star score is 4.33. The Company also provides hospice care, personal care, palliative care and high-acuity care.

 

Media Contact:    Investor Contact:
Kendra Kimmons    Nick Muscato
Vice President of Marketing & Communications    Vice President of Strategic Finance
225-299-3708    615-928-5452
kendra.kimmons@amedisys.com    nick.muscato@amedisys.com


About AssistedCare Home Health and AssistedCare of the Carolinas

AssistedCare was founded in 1994 by its current CEO, Russell Herring. Today the company provides an extensive range of in-home services throughout eastern North Carolina, including home health and long-term at home care. Home health services include skilled nursing and rehabilitation care, such as speech, occupational and physical therapy. Long-term at-home care services include personal care for adults/seniors, private duty nursing and working with the intellectual and developmental disabilities population.

About Amedisys

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 530 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com.

Forward-Looking Statements:

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “could,” “would,” “should,” “will” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, the impact of current and proposed federal, state and local vaccine mandates, including potential staffing shortages, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives


undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

#     #     #

EX-101.SCH 4 amed-20220404.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 amed-20220404_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 amed-20220404_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g348818dsp008.jpg GRAPHIC begin 644 g348818dsp008.jpg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end GRAPHIC 8 g348818g0402084142700.jpg GRAPHIC begin 644 g348818g0402084142700.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 04, 2022
Cover [Abstract]  
Entity Registrant Name AMEDISYS INC
Amendment Flag false
Entity Central Index Key 0000896262
Document Type 8-K
Document Period End Date Apr. 04, 2022
Entity File Number 0-24260
Entity Incorporation State Country Code DE
Entity Tax Identification Number 11-3131700
Entity Address, Address Line One 3854 American Way
Entity Address, Address Line Two Suite A
Entity Address, City or Town Baton Rouge
Entity Address, State or Province LA
Entity Address, Postal Zip Code 70816
City Area Code 225
Local Phone Number 292-2031
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol AMED
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 d348818d8k_htm.xml IDEA: XBRL DOCUMENT 0000896262 2022-04-04 2022-04-04 AMEDISYS INC false 0000896262 8-K 2022-04-04 0-24260 DE 11-3131700 3854 American Way Suite A Baton Rouge LA 70816 225 292-2031 false false false false Common Stock, par value $0.001 per share AMED NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d348818d8k.htm amed-20220404.xsd amed-20220404_lab.xml amed-20220404_pre.xml d348818dex991.htm d348818dex992.htm g348818g0402084142700.jpg http://xbrl.sec.gov/dei/2021 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d348818d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d348818d8k.htm" ] }, "labelLink": { "local": [ "amed-20220404_lab.xml" ] }, "presentationLink": { "local": [ "amed-20220404_pre.xml" ] }, "schema": { "local": [ "amed-20220404.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "amed", "nsuri": "http://www.amedisys.com/20220404", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d348818d8k.htm", "contextRef": "duration_2022-04-04_to_2022-04-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d348818d8k.htm", "contextRef": "duration_2022-04-04_to_2022-04-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.amedisys.com//20220404/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0001193125-22-094454-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-094454-xbrl.zip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